Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference26 articles.
1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines);National Comprehensive Cancer Network,2020
2. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N. Engl. J. Med.,2010
3. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol.,2012
4. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study;Wu;Ann. Oncol.,2015
5. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802);Zhou;Ann. Oncol.,2015
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献